(Q33344028)

26 July 2017

Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients (English)

1 reference

26 July 2017

1 reference

Gross-Goupil M

1

1 reference

26 July 2017

Lokiec F

2

1 reference

26 July 2017

Lopez G

3

1 reference

26 July 2017

Tigaud JM

4

1 reference

26 July 2017

Hasbini A

5

1 reference

26 July 2017

Romain D

6

1 reference

26 July 2017

Misset JL

7

1 reference

26 July 2017

Goldwasser F

8

1 reference

26 July 2017

1 September 2002

1 reference

European Journal of Cancer

26 July 2017

1 reference

26 July 2017

38

1 reference

26 July 2017

14

1 reference

26 July 2017

1888-1898

1 reference

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Comparison of nutritional indices and outcome in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Use of APACHE II severity of disease classification to identify intensive-care-unit patients who would not benefit from total parenteral nutrition

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Phase I and pharmacologic study of topotecan in patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Population pharmacokinetics of topotecan: intraindividual variability in total drug.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900232-0

7 January 2021

10.1016/S0959-8049(02)00232-0

Identifiers

DOI

1 reference

release_fw2gj6kjgzcwzf7p7f756kkice

26 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fw2gj6kjgzcwzf7p7f756kkice

24 November 2022

mapped directly with Wikidata item

1 reference